Two minutes, free, monthly — that's the pitch. Honest catch: no trial has proven the calendar habit itself extends life, and major guideline bodies don't endorse it as a formal screening test. What actually does the work is the part you control — knowing what a healthy testicle feels like and acting same-week on a painless lump, ultrasound rather than antibiotics. Tiny ask, big difference if your number ever comes up.
A testicular germ-cell tumor — the kind that hits the 15-to-35 age bracket harder than any other solid cancer — almost always announces itself as one thing: a small, firm, painless lump on the testicle itself EAU 2015. Not the soft, ropy bit at the back, which is the epididymis and is supposed to feel like that. The lump itself, on the smooth body of the testicle. Non-seminoma tumors double every few weeks, which is why a lesion you couldn't quite feel last month can be unmistakable next month.
The whole reason self-examination is even plausibly useful is geometry. The testicle is a surface organ. A painless lump on the testicle itself is the presenting sign in about 95% of cases, so feeling for one is a high-fidelity check. The chain you're hoping to engineer goes: lump → scrotal ultrasound this week → urology referral → outpatient surgery → done. A tumor caught while it's still inside the testicle clears at around 99% five-year survival in U.S. registry data SEER 2024. Once it's spread to distant nodes or lungs, the same disease drops to about 73% — and that lower number is what's behind a rougher decade of survivorship.
What the trials actually show
There are no trials. The 2011 Cochrane review searched for any randomised study comparing self-examination — or any other testicular cancer screening — against no examination, and found zero Ilic and Misso 2011. The U.S. Preventive Services Task Force ran the parallel evidence review and landed on a "Grade D" recommendation, which in their grammar means: actively recommend against routine screening of asymptomatic men.
Where the observational case starts to look real, it gets shakier on inspection. Yes, men who present with advanced disease typically describe longer intervals between noticing something off and seeing a doctor — three to six months is a common gap Moul 2007. But the same series can't tell you whether the men who noticed sooner did so because they self-examined, or because they were the kind of person who pays attention to their body in general — the same person who flosses, who knows their resting heart rate, who books the annual physical. Awareness campaigns reliably shift short-term knowledge and self-reported practice. Nobody has shown the shift produces a measurable change in the stage at which the tumor turns up Saab et al 2018.
Settled position, in plain terms: this is awareness, not screening. Calling it a screening test borrows the word from mammography and colonoscopy and earns the borrow nowhere.
What's actually at stake
The honest population number first: roughly 1 in 250 American men get testicular cancer over a lifetime SEER 2024. The vast majority of men reading this will never have it, and the practice will produce nothing measurable in their life. Any pitch that hides that number is selling.
If your number does come up, the gap between catching it early and catching it late is real and traceable. A small tumor caught while it's still inside the testicle is essentially one bad week. Outpatient surgery through a small incision, a few weeks of recovery, an optional sperm-bank visit before the operation, and then a surveillance schedule of imaging and tumor-marker blood draws every few months for the next three to five years EAU 2015. Most men in this column never need chemotherapy at all.
The same disease, found late, is three to four cycles of cisplatin-based chemotherapy — the protocol Larry Einhorn worked out in the late 1970s, the reason testicular cancer is curable at all Einhorn 2002. The chemotherapy works, which is why survival is still good even at the late stages. What it leaves behind is the thing nobody warns you about: a measurably higher rate of cardiovascular disease, secondary cancers, hearing damage, nerve pain in the hands and feet, and reduced fertility over the decades that follow. The five-year survival number is the headline; the next thirty years is what actually changes.
How to do it
Pick a moment after a warm shower, when the scrotal skin is loose. Hold one testicle at a time between your thumb and the first two fingers, and roll it slowly. You're feeling for the surface of the testicle itself, not the soft ropy structure behind it — that's the epididymis, that's normal. What you're looking for is one of: a hard pea-sized or larger lump that wasn't there last time, a real change in size between the two sides, a feeling of heaviness, or a dull ache that doesn't go away. Most lumps men find won't be cancer — they'll be cysts on the epididymis, varicose veins on the cord, or pockets of fluid around the testicle. But anything firm and fixed and on the testicle itself is the same-week ultrasound bucket.
Monthly is the textbook cadence. In practice, anywhere between every shower and every few months is enough — you mostly need to know what your normal feels like, so that when something changes you actually notice. The lever isn't the calendar; it's the noticing.
Where it goes wrong
Three failure modes account for almost every late presentation. The first is the man who finds the lump and waits — embarrassment, denial, "it'll probably go away" — and shows up three to six months later when the lump is harder to ignore Moul 2007. Self-examination addresses noticing the lump; it doesn't address acting on it. If you find something, the next step is the doctor, this week.
The second is the doctor who hears "lump and ache" and prescribes antibiotics for presumed epididymitis. The infection is real, can coexist with the tumor, and is the right call for some men — but the move that doesn't fail is going to ultrasound first EAU 2015. If you've been on antibiotics for a couple of weeks and the lump hasn't budged, that's the cue to push for imaging.
The third failure mode is the man who finds a benign lump, gets the workup, learns it was a spermatocele, and quietly decides the whole practice was a waste of time. Most lumps men find won't be cancer — that's a feature, not a bug. The default response to a new firm lump should still be ultrasound this week, regardless of how many previous false alarms ended up benign.
What most guides get wrong
Pain means cancer. The opposite, more often than not — the textbook presentation is painless. About 70–80% of testicular germ-cell tumors are painless when first noticed Moul 2007. A red, hot, painful testicle is more likely to be epididymitis or torsion (the second of which is its own emergency). Pain alone is not a reliable cancer sign; painlessness is.
This is the man's version of mammography. Not really. Testicular cancer is about thirty times rarer than breast cancer, the baseline cure rate is already around 95% at five years before any screening enters the picture SEER 2024, and no trial has ever earned the comparison Ilic and Misso 2011. Marketing self-exam as "men's mammography" overstates what it does and hides the part that actually matters — fast response to a painless lump.
Testicular cancer is a death sentence. Far from it. Five-year relative survival in U.S. data sits around 95% overall SEER 2024. That number got there in the early 1980s, on the back of Einhorn's cisplatin protocol — well before any self-exam campaign reached scale Einhorn 2002. The reason this cancer is curable is the chemistry, not the calendar reminder.
Every lump is cancer. Most lumps men find on themselves are benign — hydroceles, varicoceles, spermatoceles, epididymal cysts. The job of self-exam isn't to diagnose. It's to notice the new firm lump and get yourself to ultrasound.
Who should pay more attention
Incidence peaks in the early 20s through mid-30s and tapers from there, with a smaller bump after age 55 SEER 2024. The 25-year-old reader has the highest absolute exposure to this disease. Caucasian men have roughly four to five times the rate of men of African descent in U.S. registry data; Northern European countries see higher rates still Huyghe et al 2003.
Five groups carry meaningfully elevated lifetime risk: a personal history of cryptorchidism (roughly 3–5 times the baseline rate, even after the surgical correction in childhood), a father or brother with testicular cancer (about four times for sons, eight to ten times for brothers), prior cancer in one testicle (about twelve times the risk in the remaining one), Klinefelter syndrome, and clinically diagnosed infertility Wood and Elder 2009. None of this changes the population trial evidence — but the absolute risk in these groups is high enough that several urology societies recommend self-exam alongside annual clinician check, even though the routine recommendation against screening still stands for everyone else.
What "caught early" actually looks like
In the rare event that the lump is real and the chain holds — same-week ultrasound, urologist within days, surgery within a couple of weeks — the version of you who caught it has roughly the following next year. One outpatient inguinal orchiectomy through a small groin incision. Six to eight weeks back to normal physical activity. An optional sperm-bank visit before the operation if you might want kids later. A surveillance schedule of imaging and tumor-marker blood draws every few months for the next three to five years EAU 2015. Five-year survival around 99% SEER 2024. No chemotherapy for the majority of seminomas and a clear majority of non-seminomas at this stage — surveillance after surgery is the standard.
The version that didn't catch it spends most of a year on chemotherapy and then carries the late effects forward — measurably higher rates of cardiovascular disease, secondary cancers, neuropathy, hearing damage, and fertility loss over the decades that follow Einhorn 2002. Which version you get is partly geometry — whether the tumor had already started moving when it became big enough to feel. The remaining variable is the speed of the chain from the moment you notice something different.
Adjacent reading
Nearby topics worth knowing about: sperm freezing before any planned testicular surgery; the long-term survivorship picture for men a decade after cisplatin chemotherapy; the management of varicoceles and hydroceles (the common benign lumps you'll most likely find first); undescended testicle in childhood, the most common surgically-correctable risk factor; and routine annual checkups for men with a family history of testicular cancer.
- — The testicles you check for lumps also make sperm — planning a family? A one-cup semen analysis is the matching fertility test.
- — Some testicular tumours announce themselves as breast tissue in men — another reason to check.
- — A groin bulge that comes and goes is usually a hernia, not a testicular mass — different lump, different doctor.
- — Same five-minute monthly habit as your skin check — both catch cancers early, when they're still easy to cure.
- — Not every scrotal finding is sinister; a soft bag of worms above the testicle is usually just a varicocele.
Substance and claimed effects
Testicular self-examination (TSE) is a monthly palpation of each testis, performed by the man himself, intended to detect a painless intratesticular mass that may be the presenting sign of a testicular germ-cell tumor (TGCT). The technique was popularised in the 1970s and 1980s alongside the recognition that TGCT is the most common solid malignancy in men aged 15–35 and that earlier presentation correlates with lower clinical stage at orchiectomy. The implicit causal chain TSE claims: regular palpation → earlier detection of an otherwise asymptomatic mass → shorter patient delay → lower stage at diagnosis → fewer cycles of BEP chemotherapy → reduced late toxicity → marginal mortality reduction. Each link is mechanistically plausible; few are formally tested. This entry covers all four consequences named in the brief — early detection, time to evaluation, treatment stage at diagnosis, and survival — plus the relevant counterweights: false-positive findings, downstream investigations (ultrasound, occasional diagnostic orchiectomy of benign disease), and the brute fact that overall five-year survival for TGCT is already ~95% before any screening modality is applied (NCI SEER 2024).
Evidence by addressing question
Mechanism
TGCTs arise from intratubular germ-cell neoplasia and present in roughly 95% of cases as a painless, firm nodule on the testicular parenchyma — distinct from the soft, ropy epididymis at the posterior pole (Albers et al, EAU 2015). Seminomas tend to be smooth and rubbery; non-seminomas are more nodular and heterogeneous. Lesions are reliably palpable above ~5 mm. Doubling times for non-seminoma are short (10–30 days), so a lesion just below the palpation threshold can grow into a clearly palpable mass over weeks. Spread is initially lymphatic to retroperitoneal nodes, then haematogenous to lung. Stage at diagnosis is the dominant prognostic axis: localised disease (Stage I) confers 99% 5-year relative survival; regional 96%; distant 73% in current SEER data (NCI SEER 2024). The mechanistic claim of TSE is straightforward: regular palpation samples the testis frequently enough to catch the mass while still parenchymal, when orchiectomy alone is curative in roughly 80% of Stage I seminomas and 70% of Stage I non-seminomas, sparing systemic chemotherapy.
Evidence
The defining empirical fact about TSE is that no randomised controlled trial has ever evaluated whether the practice improves stage at diagnosis, survival, or mortality. The 2011 Cochrane review searched explicitly for RCTs of TSE or any other testicular cancer screening modality and found none (Ilic & Misso 2011). The U.S. Preventive Services Task Force reaffirmation in 2011 reached the parallel conclusion: the evidence is inadequate to determine the benefits of screening for testicular cancer, and the documented harms (false-positive findings, anxiety, follow-up scrotal ultrasound, occasional diagnostic orchiectomy for benign disease) outweigh the unproven benefit; the recommendation is Grade D — actively recommend against routine screening in asymptomatic adolescent and adult males (Lin & Sharangpani 2010; USPSTF 2011). A U.S. cost-utility analysis modelled TSE under favourable assumptions and concluded the practice could be cost-saving versus no examination only at very low downstream investigation costs; under typical referral costs the model tilts unfavourable (Aberger et al 2014). Observational stage-versus-delay associations are mixed: case series consistently report that men whose tumours present at advanced stage had longer symptom-to-orchiectomy intervals, but the same series cannot distinguish whether shorter delay is caused by TSE or by the same general health literacy that predicts every screening behaviour (Moul 2007). A systematic review of TSE awareness interventions found they reliably increase short-term knowledge and self-reported practice but did not track downstream changes in tumour stage or mortality (Saab et al 2018).
Protocol
The endorsed technique, where it is endorsed at all, is monthly examination after a warm shower or bath when the scrotal skin is loose. Each testis is cradled in turn, rolled between thumb and forefingers, and inspected for: a painless firm intraparenchymal lump, a change in size or consistency, asymmetry that was not there last month, a feeling of heaviness, or dull ache. The epididymis at the posterior-superior surface is normal and frequently mistaken for an abnormality on first attempts; the spermatic cord is normal as well. Any new firm, fixed, intratesticular mass warrants same-week scrotal ultrasound (the single highest-yield diagnostic step) and urology referral — not an empiric antibiotic course. Time on task: ~2 minutes per month. The American Cancer Society offers TSE as an option without a formal population recommendation; the European Association of Urology and the U.S. Preventive Services Task Force decline to endorse routine TSE in average-risk men but support patient awareness of normal testicular feel and prompt evaluation of any change (EAU 2015; USPSTF 2011; ACS 2024). For risk-enriched populations (history of cryptorchidism, family history, prior contralateral TGCT, infertility, Klinefelter), self-examination plus regular clinician examination is more commonly recommended despite the absence of trial-grade evidence (Wood & Elder 2009).
Contraindications
None biological. The relevant harm taxonomy is psychological and procedural: a false-positive palpation triggers patient anxiety, an unscheduled clinician visit, scrotal ultrasound, and rarely operative exploration for what turns out to be a benign condition — varicocele, spermatocele, epididymal cyst, hydrocele, lipoma of the cord, or a normal epididymis misperceived as a mass. In primary-care series, benign findings on self-detected scrotal abnormality outnumber malignant by roughly two orders of magnitude. The USPSTF cites this asymmetry as the structural basis for its net-negative net-benefit assessment (USPSTF 2011; Lin & Sharangpani 2010).
Misconceptions
Several reader-relevant misconceptions recur. Testicular cancer presents with pain. In roughly 70–80% of cases the presentation is painless; pain more commonly reflects epididymo-orchitis (which can also coexist) (Moul 2007). Self-examination is comparable to mammography. The analogy fails on incidence (testicular cancer is roughly 30× rarer than breast cancer in the U.S.) and on baseline cure rate (already ~95% at five years versus pre-screening breast cancer survival). Any scrotal lump is cancer. The vast majority of palpable scrotal lumps are benign — hydroceles, varicoceles, spermatoceles, epididymal cysts. Mortality from TGCT is high. Overall five-year relative survival in the U.S. is 95.2% (NCI SEER 2024); five-year survival exceeded 90% by the late 1980s, before any TSE campaign generated meaningful population uptake, and the mortality decline tracks the introduction of cisplatin-based chemotherapy by Einhorn and colleagues — not screening practice (Einhorn 2002).
Audience
Highest incidence is between ages 20 and 34, with smaller peaks in infancy and after age 55 (Huyghe et al 2003; NCI SEER 2024). Caucasian men have roughly 4–5× higher incidence than men of African descent in U.S. registry data (NCI SEER 2024). Risk-enriched subgroups warrant heightened awareness: history of cryptorchidism increases relative risk roughly 3–5× even after successful orchidopexy (Wood & Elder 2009); a first-degree relative with TGCT raises risk roughly 4× for sons and 8–10× for brothers; prior unilateral TGCT confers ~12-fold risk of metachronous contralateral cancer; infertility and Klinefelter syndrome are smaller but real risk amplifiers. None of these flips the trial evidence base for TSE — but the absolute risk in these groups is high enough that several urological societies recommend self-examination alongside annual clinician exam.
Failure-modes
Three failure modes recur in case series. First, patient delay despite a palpable lesion. Median delay between noticing a lump and seeking evaluation runs roughly 3–6 months in the available series — longer than the delay between presentation and orchiectomy — because embarrassment, denial, and absence of pain all defer presentation (Moul 2007). TSE addresses noticing the lump; it does not address acting on it. Second, physician delay. Initial misdiagnosis as epididymitis with an empiric antibiotic course can delay orchiectomy by weeks; the highest-yield single intervention is moving directly to scrotal ultrasound (Moul 2007; EAU 2015). Third, false-positive cascades — the man who self-examines, finds a benign lump, gets a sonogram, learns it is a spermatocele, and concludes the practice is pointless. This pattern erodes longitudinal compliance.
Stakes
The honest population-level stakes for an asymptomatic adolescent or adult man: vanishingly small (lifetime risk ~0.4% in the U.S.; NCI SEER 2024). The conditional stakes if a tumour is present: substantial. The difference between Stage I disease at orchiectomy and Stage III disease is roughly 3–4 cycles of cisplatin-based BEP chemotherapy, a five-year survival of ~73% rather than 99%, and a documented increase in late effects — cardiovascular disease, secondary malignancy, neurotoxicity, hearing loss, infertility (Einhorn 2002; NCI SEER 2024). Whether TSE shifts case-mix toward Stage I has not been formally shown in any randomised trial, but the conditional gradient is real and traceable.
Payoff
The narrow payoff: in the rare event of a tumour, a self-detected Stage I seminoma orchiectomy is roughly a six-week interruption of normal life — outpatient inguinal orchiectomy, optional sperm-bank visit, then surveillance imaging schedule for 3–5 years — with 99% 5-year survival. The broad payoff: replacing free-floating anxiety about testicular cancer with a procedure that the man controls and a clear escalation path (lump → ultrasound → urologist). The payoff is not a measurable population mortality reduction; the literature does not support that claim. Onset latency: the benefit, if any, materialises only on the rare positive event.
History
The mortality story of testicular cancer is dominated by treatment, not screening. Before 1974, metastatic non-seminoma had a 5-year survival of approximately 10%. Einhorn's introduction of cisplatin–vinblastine–bleomycin (and subsequent refinement to BEP) raised cure rates for metastatic disease above 80% within a decade (Einhorn 2002). The U.S. mortality decline from roughly 10 per 100 000 to roughly 0.3 per 100 000 occurred between the mid-1970s and mid-1980s, before TSE campaigns had appreciable population uptake. Awareness campaigns followed the cure; they did not produce it. Sustained attention to TSE by survivor-advocacy organisations renewed visibility in the 2000s; the USPSTF reaffirmation against routine screening in 2011 reflects the field's settled judgment (USPSTF 2011).
Alternatives
Alternative screening modalities have been evaluated and rejected for routine population use on the same evidence base. Routine clinician examination yields similar harms with marginal additional sensitivity. Routine scrotal ultrasound in asymptomatic men adds substantial false-positive cost and is not endorsed. Tumour markers (AFP, β-hCG, LDH) are diagnostically and prognostically essential but lack sensitivity for asymptomatic screening — they are negative in ~40% of seminomas and a substantial minority of non-seminomas (EAU 2015). The de facto alternative the catalogue endorses is awareness without ritual: knowing what a testis normally feels like and what a painless intratesticular lump means, with a low-frequency check-in cadence and a rapid escalation path.
Out-of-scope
Adjacent topics not covered here: BEP late effects and long-term follow-up of TGCT survivors; fertility preservation and cryopreservation before orchiectomy; ultrasound technique and interpretation; cryptorchidism management; varicocele and hydrocele management; clinical staging and chemotherapy choice; testosterone replacement after bilateral orchiectomy.
The credibility range
Optimist case
TSE is free, biologically obvious, and harmless at the individual level. Palpation of a superficial paired organ is a high-fidelity sample for a small population of lesions whose presenting sign is a palpable mass. The absence of RCT-grade evidence is a research gap, not a refutation: TGCT is rare enough that an adequately powered trial would require hundreds of thousands of person-years, and no funder has prioritised it (Ilic & Misso 2011). Observational series consistently show that delay correlates with stage (Moul 2007); awareness interventions reliably shorten symptom-to-presentation intervals at scale (Saab et al 2018). The catastrophe-avoidance asymmetry is favourable: monthly palpation costs two minutes; missing a Stage I tumour that progresses to Stage III risks BEP exposure, late cardiovascular disease, fertility loss, and a quarter chance of mortality (Einhorn 2002). Even a small probability of stage downshift makes TSE rational at the individual level — especially in risk-enriched groups.
Skeptic case
Recommending against routine TSE is not radical scepticism; it is the published position of the U.S. Preventive Services Task Force, reaffirmed after a methodical evidence review (USPSTF 2011; Lin & Sharangpani 2010). There are no trials. The observational stage-vs-delay association is confounded by general health literacy. False-positive rates from self-detected scrotal abnormalities are high; benign masses outnumber malignant by orders of magnitude. Survival is already ~95% at five years (NCI SEER 2024), and the mortality decline tracks cisplatin, not awareness (Einhorn 2002) — so the population mortality signal to which TSE could plausibly contribute is small to absent. Marketing TSE as a "screening test" confuses an awareness behaviour with a tested intervention.
Author's call
The catalogue's editorial line: be honest about the evidence. TSE has no RCT support and is not endorsed for routine population screening by any modern guideline body. But for the individual man, the practice is approximately free, the harms are small and rarely catastrophic, and the conditional benefit — should a tumour actually present — is meaningful. The lever that matters most is not the calendar ritual but the response to a painless intratesticular lump: same-week ultrasound, urology referral, no antibiotic course. The article lands on knowledge of normal testicular feel + a low-frequency self-check cadence + a rapid escalation path — not religious monthly compliance — and is explicit that the practice has not been shown to extend population survival. evidence scores low (Grade D from USPSTF, zero RCTs); controversy scores low-moderate (the field is mostly aligned on "not formal screening," with survivor-advocacy organisations pushing harder than guideline bodies); longevity scores marginal (conditional benefit only).
Stakeholder and incentive map
Survivor-advocacy organisations (Movember, Testicular Cancer Society, historically the Lance Armstrong Foundation) push TSE awareness as part of their organisational identity; messaging often outruns the evidence. The urological community is split: practising urologists frequently recommend self-examination to their at-risk patients and TGCT survivors while professional guideline bodies (EAU, AUA) decline to endorse routine screening of asymptomatic men. National screening bodies (USPSTF in the U.S., the UK National Screening Committee) explicitly recommend against. There is no significant commercial supply chain — no test, no device, no drug — which is part of why funding for a definitive RCT has never materialised. Mild counter-pressure comes from referrals: urology practices receive scrotal-ultrasound referrals from self-detected abnormalities that are benign in the overwhelming majority of cases.
Population variability
The peak incidence window — 20 to 34 — is also the population most likely to comply with a monthly behaviour cue, though self-reported compliance in U.S. surveys is generally low (15–30% range), with awareness consistently outrunning practice (Saab et al 2018). Men over 55, the third demographic bump, are typically under broader medical surveillance and may pick up the lesion incidentally. Caucasian incidence runs roughly 4–5× the African-American rate in U.S. registry data; Northern European incidence runs higher still, with notable geographic variation (Huyghe et al 2003). The risk-enriched subgroups named above (cryptorchidism, family history, prior contralateral TGCT, infertility, Klinefelter) carry absolute lifetime risks high enough that the individual calculus shifts toward more active surveillance, including clinician examination at routine visits (Wood & Elder 2009).
Knowledge gaps
The defining gap is the absence of any randomised trial of TSE versus no examination versus clinician examination versus ultrasound, with stage at diagnosis or mortality as the endpoint. Adequately powered detection of a stage-shift effect would require on the order of 100 000 person-years per arm given U.S. incidence; no national funder has prioritised this and the commercial supply chain that funds equivalent screening trials (mammography, colonoscopy) is absent here. Secondary gaps: whether TSE in risk-enriched populations (cryptorchidism, family history, prior contralateral TGCT) shows a stage-shift effect that the general-population evidence cannot detect; whether digital interventions (apps, monthly reminders) translate awareness into sustained compliance; whether false-positive cascades produce measurable erosion of long-term self-examination practice. Evidence that would change the author's call: a positive RCT in any of the risk-enriched populations.
The four named consequences. The brief named early detection, time to evaluation, treatment stage at diagnosis, and survival. All four are covered. The evidence and failure-modes sections carry the bad-news pieces honestly: no RCTs of TSE exist (Ilic and Misso 2011), the stage-vs-delay correlation is confounded by general health literacy (Moul 2007), the mortality decline since the 1970s tracks cisplatin chemotherapy, not screening (Einhorn 2002). The stakes and payoff sections carry the conditional-benefit pieces (Stage I ≈99% 5-year survival vs Stage III ≈73%, per SEER 2024). Nothing in the brief was silently dropped.
Action and cadence. Action do over know because the substance is a physical behaviour (palpation), even though the article lands on "noticing matters more than the calendar." Cadence as-needed is a vocabulary gap: there is no monthly token in the closed cadence set. weekly overstates frequency, yearly understates it. as-needed honestly captures the real-world pattern (irregular, prompted by shower or change-detection rather than calendar) even though the textbook prescription is monthly. Worth proposing a monthly cadence token if other entries hit the same gap.
Longevity scored 1, not 0 or 2. Zero would be dishonest because the Stage-I-vs-Stage-III gradient is real and traceable to a downstream behaviour the substance enables. Two would overstate population effect — lifetime incidence is ~0.4% and the mortality decline tracks treatment, not screening. 1 ("marginal contribution") fits: real conditional benefit, negligible population effect.
Evidence scored 2, not 1. Grade D from USPSTF could suggest a 1, but the mechanism is genuinely plausible and the evidence is sparse rather than negative — Cochrane found no trials, not failed trials (Ilic and Misso 2011). The anchor 2 ("sparse or contested literature; mechanism plausible but trials thin or mixed") matches.
Controversy scored 2. USPSTF, EAU, AUA, UK NSC all decline to endorse routine TSE; survivor-advocacy organisations and many practising urologists recommend it for patient empowerment and in risk-enriched groups. Both sides agree absolute risk is low and trial evidence is absent — minor pushback at the margins, not a foundational fight.
Audience scoping. Restricted to males 18–39 and 40–59. The 60+ band was excluded because the third small demographic bump after 55 is dwarfed by the under-35 peak and these men are typically under broader medical surveillance generally; the substance still applies but the catalogue's prime reader for this entry is younger.
Excluded from the article. Inguinal orchiectomy technique, BEP regimen specifics, retroperitoneal lymph node dissection, post-treatment surveillance imaging cadence — clinical management territory beyond the friend-test reader's needs. Routine clinician examination as a screening modality was treated as part of the same evidence base, not a separate alternative, because the USPSTF Grade D applies to all forms of routine screening symmetrically. Patient-delay psychology (embarrassment, denial) is named in failure-modes but not unpacked further.
Future-link candidates. Cryptorchidism (history and adult surveillance implications), varicocele and hydrocele (the benign lumps men find first), sperm cryopreservation before any planned orchiectomy, long-term survivorship after cisplatin chemotherapy (cardiovascular, secondary cancer, neuropathy, hearing, fertility late effects), and a general "noticing change in your own body" mindset entry. The audience paragraph on risk-enriched groups would benefit from cross-links once cryptorchidism and family-history-screening entries exist.
Separate-entry candidates. Long-term survivorship after testicular cancer (BEP late effects, cardiovascular surveillance, fertility recovery) is substantial enough to warrant its own entry — the article gestures at it in stakes and payoff but doesn't go deep. A hereditary-risk-driven screening entry analogous to BRCA framing for breast cancer would cross-cut several catalogue categories.
Testicular Self-Examination
Approximately two minutes per month after a warm shower; no equipment. Self-reported compliance in U.S. surveys is 15–30%, suggesting forgetting (not friction in the act itself) is the operative obstacle (Saab et al 2018).
USPSTF Grade D, reaffirmed in 2011 — recommends against routine screening (USPSTF 2011; Lin & Sharangpani 2010). The 2011 Cochrane review identified no RCTs of TSE or any other testicular cancer screening modality (Ilic & Misso 2011). Mechanism is plausible; observational stage-vs-delay correlations exist but are confounded by general health literacy (Moul 2007).
Conditional only: if a germ-cell tumour is present, earlier presentation correlates with Stage I disease (~99% 5-year relative survival) versus Stage III (~73%) and avoids 3–4 cycles of cisplatin-based BEP and its late effects (Einhorn 2002; NCI SEER 2024). Population mortality effect is negligible at ~0.4% lifetime incidence and has never been demonstrated in an RCT (Ilic & Misso 2011).